DLH to Announce Fiscal 2026 First Quarter Financial Results
ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of...
Day: February 2, 2026
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week...
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will...
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to...
Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence
Reinforcing AbinoNutra® NMN as a clinically validated, science-driven ingredient for NAD⁺ support and healthy longevitySHELTON, Conn., Feb. 02, 2026 (GLOBE...
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
XanaMIA trial fully enrolled with final results expected in November 2026SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited...
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor...
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS...
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or...
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical...
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals...
Iridex Announces Plans to Relocate Headquarters
Move expected to generate significant cost savingsMOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide...
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE®...
Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Feb. 02, 2026...
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3...
Guidelight Expands to California with Opening of Los Angeles Clinic
Leading Provider of Evidence-Based Mental Health Treatment Brings Services to West LALOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Guidelight,...
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well...
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel...